EU/3/16/1811: Orphan designation for the treatment of glioma

5-aminolevulinic acid

Overview

On 12 January 2017, orphan designation (EU/3/16/1811) was granted by the European Commission to Centre Hospitalier Universitaire de Lille, France, for 5-aminolevulinic acid for the treatment of glioma.

Key facts

Active substance
5-aminolevulinic acid
Medicine name
-
Intended use
Treatment of glioma
Orphan designation status
Positive
EU designation number
EU/3/16/1811
Date of designation
12/01/2017
Sponsor

Hemerion Therapeutics
37 Rue Denis Papin 
59650 Villeneuve d’Ascq 
France
Email: cd@hemerion.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

DateUpdate
March 2023The sponsor's address was updated.
December 2020The sponsorship was transferred to Hemerion Therapeutics, France. 

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating